A randomized, double blind, placebo controlled trial was recently conducted to measure the effect of Q-Gel Coenzyme Q10 in patients with end stage heart failure. The results at the end of the twelve week trial were dramatically positive for the use of Q-Gel CoQ10 in patients with congestive heart failure and end stage heart failure. Treatment with Q-Gel for 12 weeks was associated with a significant reduction in left ventricular wall thickness, left ventricular mass, ejection fraction and end diastolic, end systolic volumes and more.
The Q-Gel Coenzyme Q10 used in this study was Q-Gel Forte, (our 30 mg product), at 120 mg per day.
We have reproduced the write up on this study below. As you will quickly notice, it is pretty technical being written for cardiologists and other health care professionals. You may want to consider printing a copy of this page and discussing the possibility of using Q-Gel CoQ10 with your local health care professional.
EFFECT OF Q GEL (COENZYME Q10) IN PATIENTS WITH
ENDSTAGE HEART FAILURE TARGETED FOR HEART
In a randomized, double blind, placebo controlled trial, the effects of oral treatment was compared for 12 weeks in 21 (Hartgard group A) and 21 (placebo group B) patients with heart failure diagnosed by two-dimensional echocardiography (Two D echo). Patients were stratified into congestive heart failure (9 vs 10) and end stage heart failure (ESHF, 12 vs 11) and then divided into two groups. The etiology of ESHF was ischemic (9 vs 9) and dilated (3 vs 2) cardiomyopathy and most of these patients were receiving standard treatment including ACE-inhibitors, furosemide, beta blockers and digoxin.
After treatment with Q gel for 12 weeks, there was a lower incidence of dyspnoea (14.3 vs 52.4%, P< 0.05), palpitation (9.5 vs 85.7%, P< 0.02) and weakness (19.0 vs 52.4%, P< 0.05) in the Q gel group than in the placebo one. NYHA class III and IV heart failure were comparable (71.4 vs 85.7%) at entry to the study. However after 12 weeks, there was a significant decrease in these patients in the Q gel group but not in the placebo one (14.3 vs 85.7%, P<0.05). TBARS, diene conjugates and MDA which are parameters of oxidative damage, showed significant decline in the treatment group compared to placebo group. Angiotensin converting enzyme (ACE) level showed no significant differences at entry to the study, however after 12 weeks there was a significant decline in the plasma level of ACE (54.6 + 5.6 vs 90.2 + 7.0 IU, P < 0.05) in the intervention group than control group. Left ventricular wall thickness (13.4 + 2.7 vs 14.1 + 3.1mm), left ventricular mass (242 + 70 vs 245+ 75g), ejection fraction (47.5 + 5.6 vs 45.6 +4.2%). End diastolic volume (108 + 3.2 vs 107 + 3.0ml) end systolic volume (62.6 + 1.6 vs 63.0 + 1.7ml) and sphericity index (1.62 + 0.25 vs 1.62 + 0.31) were comparable at entry to the study in the two groups. However, treatment with Q gel for 12 weeks was associated with a significant reduction in left ventricular wall thickness, left ventricular mass, ejection fraction and end diastolic and end systolic volumes and a significant increase in the sphericity index in the intervention group compared to control group. Adverse effects of Hartgard included nausea (n=6), vomiting (n=40), loose stools (n=2). It is possible that Q gel may be used as an adjuvant therapy together with ACE-inhibitors, diuretics, digoxin and beta blockers in the management of patients with heart failure and ESHF. Coenzyme Q10 might contribute to prevention of remodeling and to regression of hypertrophy by improving myocardial bioenergetics and endothelial function. The Q-Gel Coenzyme Q10 used in this study was Q-Gel Forte, (our 30 mg product), at 120 mg per day.
Dosage depends on many different factors, some of the MD's who buy from us suggest the following dosages for their patients with heart failure: a jump start of up to 200mg Q-Gel CoQ10 for first 2-3 weeks and then 120mg per day. If needed, you can go back up to the 200 mg per day level depending on your body’s needs.
The study entitled “EFFECT OF Q GEL (COENZYME Q10) IN PATIENTS WITH ENDSTAGE HEART FAILURE TARGETED FOR HEART TRANSPLANTATION” was presented at the Third Conference of the International Coenzyme Q10 Association held in London on November 22-24, 2002. The study was done at Government Medical College, Amritsar, Medical Hospital and Research Centre, Moradabad, India. Authors: Adarsh Kumar, N.S.,Kartikey, M.A. Niaz, R.B. Singh. Correspondence can be directed to: Dr. Adarsh Kumar, Professor of Cardiology, Government Medical College, 2121 Ranjut Ave., Amritsar (Pb) 143001, India